Patent Application
20240026264
Bioreactors, which are apparatuses in which biological reactions or processes can be carried out on a laboratory or industrial scale, are used widely within the biopharmaceutical industry. Bioreactors can be used to produce all different types of bioproducts. Bioproducts can include, for instance, cell cultures and materials derived from cell cultures including vaccines, beverages, biofuels, bioenergy, biochemicals, antibiotics, amino acids, enzymes, monoclonal antibodies, monomers, proteins, food cultures, biopolymers, alcohols, flavorings, fragrances, and the like.
Cell cultures are typically grown in batch processes where the biological material remains in the bioreactor until the end of the reaction time. In certain of these processes, fluid medium contained within the bioreactor can be periodically or continuously removed and resupplied in order to replenish nutrients contained within the fluid medium and for possibly removing damaging by-products that are produced during the process.
During the growth and harvesting of cell cultures, various fluids are formulated and fed to different process equipment. Such fluids, for instance, can include nutrient mediums, various different types of reagents, buffer formulations, and the like. In addition, fluids are also conveyed between different process components. For example, cell cultures are typically grown in bioreactors and then fed downstream to different purification processes. The purification processes can include chromatography skids, filtration devices, and the like. Each of these different steps of the process can also produce product and byproduct streams that are removed during the process and stored in different containers, such as bioprocess bags.
As the development of biologics continue, the ability to mass produce cell cultures in large volumes in order to produce bioproducts is imperative. The recent coronavirus pandemic, for instance, has further illustrated the need for robust processes for producing biologic products. For example, vaccines are currently being produced and tested against the coronavirus strain. Many of these vaccines are based upon biological products obtained from microorganisms, such as messenger RNA therapeutic deliveries. Once a vaccine has been tested and approved, it will be necessary to produce conceivably billions of doses of the vaccine. Thus, there is a need to produce large scale cell culture systems that operate reliably and efficiently.
During the transfer of fluids in larger scale biological processes, larger bioprocess tubes are needed in order to accommodate the volumetric flow rates of the fluids. After fluid transfer, many of these bioprocess tubes must then be disconnected from the different process equipment. Currently, the only solution for connecting and disconnecting larger bioprocess tubes is to purchase bioprocess tubes with automatic disconnects or to install disconnects on the tube. These disconnect devices, however, can form weakened areas along the bioprocess tube and are susceptible to leakage during high pressure operations. In addition, not only are the disconnect devices expensive, but they also provide no ability to make adjustments regarding the location on the bioprocess tube where a disconnection may be desired. Consequently, preassembled disconnect devices are not only impractical, but can also reduce the efficiency of the overall process.
In view of the above, a need exists for a system and method for easily disconnecting mid-scale and large scale bioprocess tubes in a biological process.
The present disclosure is generally directed to a system and method for growing, harvesting and purifying cell cultures and bioproducts produced therefrom. More particularly, the present disclosure is directed to a bioprocess system and method capable of producing relatively large batches of biological materials. The components contained within the system are all sized for high throughputs in order to produce all different types of beneficial bioproducts, including vaccines for different viruses. In accordance with the present disclosure, the bioprocess method and system include relatively large bioprocess tubes that convey fluids and connect the different components. The present disclosure is directed to a method of disconnecting the bioprocess tubes after fluid flow in an efficient and sterile manner.
For example, in one aspect, the present disclosure is directed to a bioprocess system comprising a first bioprocess device and a second bioprocess device. A bioprocess tube is in fluid communication with the first bioprocess device and the second bioprocess device. The bioprocess tube comprises a thermoplastic elastomer. The bioprocess tube defines a hollow passageway having an internal diameter, an external diameter, and an external surface. The internal diameter of the bioprocess tube is greater than about 260 mm, such as greater than about 280 mm, such as greater than about 300 mm, such as greater than about 320 mm, such as greater than about 340 mm, such as greater than about 360 mm, such as greater than about 380 mm, such as greater than about 400 mm. In accordance with the present disclosure, the system further includes a separating collar for facilitating cutting of the bioprocess tube for disconnecting the first bioprocess device from the second bioprocess device. The separating collar is slidably mounted on the exterior surface of the bioprocess tube. The separating collar has a cylindrical shape and has a length that extends from a first end to a second and opposite end. The separating collar is made from a rigid and malleable material. The separating collar defines at least one pair of adjacent separating edges that extend over the length of the collar. The pair of adjacent separating edges allow the separating collar to be installed and removed from a bioprocess tube. For instance, in one aspect, pair of adjacent separating edges form a slit that extends over the length of the collar.
The separating device can be made from various different materials, such as metallic materials, polymer materials, and the like. The separating collar can be made from a single layer of material or can be made from multiple layers of material. In one embodiment, the separating collar can be made from aluminum. During cutting of the bioprocess tube, a cutting device is used to cut the separating collar and the underlying tube. During cutting, the separating collar and bioprocess tube are compressed. The separating collar is made from a material with sufficient rigidity and malleability such that after cutting the bioprocess tube, the separating collar maintains the open ends of the bioprocess tube in a closed configuration. Consequently, the separating collar is made from a material that is able to withstand the natural biasing forces of the bioprocess tube once the clamping action of the cutting tool is released.
As described above, the separating collar can define a slit along the length of the collar. The slit can have a width, in one aspect, of greater than about 0.5 mm, such as greater than about 1 mm, such as greater than about 1.5 mm, such as greater than about 2 mm, and less than about 5 mm, such as less than about 3 mm. In another aspect, the slit can be wider. For instance, the slit can have a width of greater than about 3 mm, such as greater than about 10 mm, such as greater than about 20 mm, such as greater than about 30 mm, and generally less than about 100 mm. In general, the slit should have a width that facilitates opening the collar so as to place the collar around a bioprocess tube. The length of the separating collar can generally be from about 600 mm to about 3000 mm.
In an alternative embodiment, the opposite ends of the separating collar can overlap along the slit. For example, the opposite free ends of the separating collar can overlap by greater than about 1 mm, such as greater than about 5 mm, and generally less than about 300 mm, such as less than about 15 mm.
In still another alternative embodiment, the separating collar comprises a first collar member and a separate second collar member. The first and second collar members cooperate together to form the cylindrical shape. In this embodiment, the separating collar can form two pairs of adjacent separating edges where the first collar member intersects the second collar member.
The present disclosure is also directed to a process for separating a bioprocess tube contained in a bioprocess. The method includes placing a separating collar on an exterior surface of a bioprocess tube. The bioprocess tube is made from a thermoplastic elastomer and has an internal diameter of greater than about 260 mm, such as greater than about 300 mm. The separating collar is slidably mounted on the exterior surface of the bioprocess tube. The separating collar has a cylindrical shape having a length. At least one pair of adjacent separating edges extend over the length of the separating collar. The pair of adjacent separating edges is for allowing the separating collar to be installed and removed from the bioprocess tube. The method further includes the step of cutting through the separating collar and the bioprocess tube to produce a first free end and a second free end. During cutting, the separating collar and underlying bioprocess tube are deformed, compressing the walls of the bioprocess tube together at each free end. The separating collar is made from a material with sufficient rigidity and malleability to maintain the open ends of the bioprocess tube in a closed state or condition.
In one aspect, the method can further include the step of blocking flow of fluid through the bioprocess tube upstream of the separating device using a flow stop device and blocking flow of fluids through the bioprocess tube downstream of the separating device using a second flow stop device. The flow stop devices, for instance, can comprise clamps and can be installed on each side of the separating device prior to cutting the bioprocess tube.
The present disclosure is also directed to a bioprocess apparatus comprising a separating collar as described above removably and slidably mounted on a bioprocess tube having an internal diameter greater than about 260 mm.
Other features and aspects of the present disclosure are discussed in greater detail below.
A full and enabling disclosure of the present disclosure is set forth more particularly in the remainder of the specification, including reference to the accompanying figures, in which:
Repeat use of reference characters in the present specification and drawings is intended to represent the same or analogous features or elements of the present invention.
It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only and is not intended as limiting the broader aspects of the present disclosure.
In general, the present disclosure is directed to a system and method for propagating cell cultures, harvesting the cell cultures, purifying the cell cultures and producing a biological product. Many different types of biological products can be produced according to the present disclosure. For instance, the biological product can be a protein or any other metabolite produced by the cell culture. In one embodiment, the cell culture can be used to produce a vaccine for viruses, such as recombinant messenger RNA.
Currently, a major obstacle to the production of biologics, such as vaccines, is the ability to produce the biological products on a larger scale in a reliable manner. In particular, a need exists for bioprocess systems and methods that operate at relatively high throughputs. When over-sizing the equipment and components, various obstacles can exist that may reduce efficiencies. For example, mid-scale and large-scale bioprocess systems need bioprocess tubes that have larger sizes and diameters for connecting the different components together. The present disclosure is directed to an efficient way to disconnect larger bioprocess tubes after fluid flow in order to isolate a component in the system and/or to collect a product or a byproduct in, for instance, a bioprocess bag.
For exemplary purposes only,
The bioreactor 10 can be made from various different materials. In one embodiment, for instance, the bioreactor 10 can be made from metal, such as stainless steel. Alternatively, the bioreactor 10 may comprise a single use bioreactor made from a rigid polymer or a flexible polymer film.
The bioreactor 10 can have any suitable volume. In general, however, the bioreactor 10 has a volume of greater than about 5 L, such as greater than about 50 L, such as greater than about 100 L, such as greater than about 500 L, such as greater than about 700 L, such as greater than about 1000 L, such as greater than about 1500 L, such as greater than about 2000 L, such as greater than about 2500 L, such as greater than about 3000 L, such as greater than about 3500 L, such as greater than about 4000 L, such as greater than about 4500 L, such as greater than about 5000 L. The volume of the bioreactor 10 can be even greater than about 7000 L, such as greater than about 10,000 L, such as greater than about 15,000 L, such as greater than about 20,000 L. The volume of the bioreactor 10 is generally less than about 50,000 L, such as less than about L.
In addition to the impellers 16 and 18, the bioreactor 10 can include various additional equipment, such as baffles, spargers, gas supplies, heat exchangers or thermal circulator ports, and the like which allow for the cultivation and propagation of biological cells. For example, in the embodiment illustrated in
As shown in
In the embodiment illustrated in
As shown in
Once a cell culture has been propagated in the bioreactor 10, in one embodiment, the cell culture is fed to a harvest system for harvesting a bioproduct. Not shown, for instance, the system may include a harvest tank, and a centrifuge. In many systems, the bioproduct being harvested can then be fed to downstream purification processes. For example, in
The filtration devices 42 and 46 may include a variety of filtration mechanisms. For example, in one embodiment, one of the filtration devices may comprise a tangential flow filtration (TFF) device. A tangential flow filtration device, for instance, may enable the diafiltration of the product stream. A tangential flow filtration device may include two stages; volume reduction and diafiltration. During the volume reduction step, the bulk volume of the cell culture medias is filtered out through the permeate side of the filter until a desired product concentration is reached in the holding tank. In a diafiltration stage following the volume reduction stage, the concentrated product is washed with a fluid, such as a buffer, to remove cell culture or harvest media components that are undesired or are unacceptable. Further volume reduction may also be carried out after diafiltration to reach a desired product density.
In one embodiment, the filtration devices 42 and 46 may use ultrafiltration. During ultrafiltration, the product stream is fed through a semipermeable membrane. Suspended solids and solutes of high molecular weight are retained as a retentate, while water and low molecular weight solutes pass through the membrane as the permeate. Ultrafiltration is particularly well suited to purifying and concentrating protein solutions. In one embodiment, ultrafiltration can be used with diafiltration as described above. The chromatography device 44 as shown in
The process and system of the present disclosure, for instance, can use any suitable chromatography method.
Similar to the filtration devices 42 and 46, the chromatography device 44 may also need a buffer for proper operation of the device.
As shown in
As shown in
In addition to the bioprocess devices illustrated in
As shown in
The present disclosure is generally directed to a bioprocess apparatus that can efficiently disconnect one bioprocess device from another bioprocess device at any location along a bioprocess tube that was previously used to connect the devices for fluid flow. The bioprocess apparatus of the present disclosure is particularly well suited to forming disconnects on bioprocess tubes that are used in mid-scale and large-scale systems. More particularly, the bioprocess apparatus is designed to form a separation along a bioprocess tube that has a relatively large internal diameter. In one aspect, the bioprocess device can be used to produce a sterile disconnect along the bioprocess tube.
Referring to
The bioprocess tube 110 can be made from a polymer material, particularly a thermoplastic polymer. In one aspect, the bioprocess tube 110 is made from a thermoplastic elastomer. For instance, the bioprocess tube 110 can be made from a silicone polymer. Other elastomers that may be used to produce the bioprocess tube include polyvinyl chloride polymers, polypropylene polymers, polyethylene polymers, or a polyester polymer. As used herein, a polymer can refer to a homopolymer, a copolymer, a block copolymer, a random copolymer, a terpolymer, and the like. For example, polypropylene elastomers can be used that contain a polypropylene homopolymer combined with a polypropylene random copolymer. If desired, the polymer composition used to produce the bioprocess tube 110 can contain a plasticizer.
As described above, the bioprocess tube 110 has a relatively large size capable of conveying significant fluid flow therethrough. The bioprocess tube 110 can have an internal diameter measured from the interior surface 118 and an exterior diameter measured from the exterior surface 116. In general, the internal diameter of the bioprocess tube 110 in accordance with the present disclosure is greater than about 260 mm. For instance, the internal diameter of the bioprocess tube 110 can be greater than about 300 mm, such as greater than about 350 mm, such as greater than about 400 mm, such as greater than about 450 mm, such as greater than about 500 mm, such as greater than about 550 mm, such as greater than about 600 mm, such as greater than about 650, such as greater than about 700 mm, such as greater than about 750 mm, such as greater than about 800 mm, such as greater than about 850 mm, such as greater than about 900 mm, such as greater than about 950 mm, such as greater than about 1000 mm. The internal diameter of the bioprocess tube 110 is generally less than about 2000 mm, such as less than about 1500 mm. In one particular aspect, the internal diameter of the bioprocess tube 110 is from about 260 mm to about 780 mm, including all increments of 5 mm therebetween.
The wall thickness 114 of the bioprocess tube 110 can vary depending upon various factors including the type of thermoplastic polymer used to make the bioprocess tube, and the amount of pressure that may build up within the bioprocess tube 110 during operation. In general, the wall thickness 114 is generally greater than about 5 mm, such as greater than about 6 mm, such as greater than about 7 mm, and generally less than about 12 mm, such as less than about 10 mm, such as less than about 8 mm.
Referring back to
In an alternative embodiment, the opposing ends of the separating collar 120 along the slit 122 can overlap. For example, as shown in
The slit 122 can have various different purposes. In one aspect, for instance, the slit 122 allows the separating collar 120 to be fitted over bioprocess tubes 110 that have different external diameters. In addition, the slit 122 can be used to place the separating collar 120 onto the exterior surface 116 of the bioprocess tube 110. For instance, by grasping opposite ends of the separating collar 120 along the slit 122, one can increase the size of the slit so that the separating collar 120 can be placed over the bioprocess tube 110. In an alternative embodiment, a device or tool made be used that can engage opposite ends of the separating collar along the slit 122 for providing the force necessary for the slit to open up for accommodating a bioprocess tube. In still another embodiment, the separating collar can be manufactured in an open state allowing the collar to be placed over a bioprocess tube. Once placed over the bioprocess tube, the separating collar can then be bended into a desired shape that conforms to the exterior surface of the bioprocess tube.
In addition to the above, the slit 122 also allows the separating device 120 to be slidably mounted onto the bioprocess tube 110. In this manner, the separating collar 120 can be moved to any desired location on the bioprocess tube. The ability to slide the separating collar 120 over the exterior surface 116 of the bioprocess tube 110 provides significant flexibility in determining later the best location to separate the bioprocess tube after fluid flow has stopped.
The width of slit 122 along the length of the separating collar 120 can vary depending upon the type of material used to produce the separating collar 120, the outside diameter of the bioprocess tube 110, and the like. In one aspect, for instance, the slit 122 can be relatively narrow. For instance, the slit can have a width of less than about 3 mm, such as less than about 2 mm, such as less than about 1.5 mm, such as less than about 1 mm, and generally greater than about 0.5 mm, such as greater than about 1 mm. Alternatively, the slit can be wider, especially when the separating collar 120 is to be installed on larger bioprocess tubes. For instance, the width of the slit can be greater than about 3 mm, such as greater than about 10 mm, such as greater than about 20 mm, such as greater than about 30 mm, and generally less than about 100 mm.
The length of the separating collar 120 and therefore the length of the slit can generally be anywhere from about 600 mm to about 10,000 mm and including all increments of 5 mm therebetween. The length of the separating collar 120, for instance, should be sufficient to maintain the bioprocess tube in a closed condition after cutting as will be explained in greater detail below. The upper boundary of the length is not a factor and there may be applications where the length can be greater than about 3000 mm, such as greater than about 5000 mm, such as greater than about 10,000 mm, such as greater than about 15,000 mm.
In
For example, referring to
As shown in
In an alternative embodiment, the first collar member 134 can be connected to the second collar member 136 along a hinge at a first pair of adjacent separating edges. The second pair of adjacent separating edges, on the other hand, can include a connecting device that permits the two edges to connect.
Referring to
As explained above, the separating collar 120 is first slidably mounted onto the bioprocess tube 110. The separating collar 120 can then be moved to any desired location where a disconnect operation can take place. Once positioned at the appropriate location, a cutting tool 150 as shown in
A cutting device 150 is used that compresses the separating collar 120 and bioprocess tube 110 while simultaneously cutting through both materials. For instance, the cutting device 150 can deform the separating device 120 and compress the bioprocess tube squeezing the interior wall of the bioprocess tube together. Once the bioprocess tube 110 and separating collar 120 are compressed together, the cutting device 150 cuts through both materials and forms a first free end 130 and a second free end 132 as shown in
In one embodiment, in order to ensure that no fluid drips or spills from the bioprocess tube 110 during the cutting operation, flow stop devices can be installed upstream and downstream from the separating collar 120. The flow stop device can be any suitable clamp capable of cutting off fluid flow through the bioprocess tube 110.
The material used to produce the separating collar 120 should be selected so that the separating collar 120 can be fitted over a bioprocess tube, can be compressed during a cutting process, and can maintain the free ends formed during the cutting process in a closed position. The separating collar 120, for instance, can be made from a polymer material, a reinforced polymer material, a metal, or mixtures thereof. The separating collar 120 can be made from a single layer of material or can have a multilayer design.
In one aspect, the separating collar 120 is made from a metal, such as an aluminum. The thickness of the separating collar 120 can generally be greater than about 0.5 mm, such as greater than about 0.75 mm, such as greater than about 1 mm, such as greater than about 1.1 mm, such as greater than about 1.2 mm, such as greater than about 1.3 mm, such as greater than about 1.4 mm, such as greater than about 1.5 mm. The thickness is generally less than about 4 mm, such as less than about 3 mm, such as less than about 2 mm, such as less than about 1.8 mm.
The separating device 120 can be used at any desired location within a bioprocess system, such as any place shown in the bioprocess system of
The separating collar can also be used during harvesting and purification. For instance, the separating device can be used to separate a chromatography device from a filtration device or a filtration device from a process bag.
The devices, facilities and methods described herein are suitable for culturing any desired cell line including prokaryotic and/or eukaryotic cell lines. Further, in embodiments, the devices, facilities and methods are suitable for culturing suspension cells or anchorage-dependent (adherent) cells and are suitable for production operations configured for production of pharmaceutical and biopharmaceutical products—such as polypeptide products, nucleic acid products (for example DNA or RNA), or cells and/or viruses such as those used in cellular and/or viral therapies.
In embodiments, the cells express or produce a product, such as a recombinant therapeutic or diagnostic product. As described in more detail below, examples of products produced by cells include, but are not limited to, antibody molecules (e.g., monoclonal antibodies, bispecific antibodies), antibody mimetics (polypeptide molecules that bind specifically to antigens but that are not structurally related to antibodies such as e.g. DARPins, affibodies, adnectins, or IgNARs), fusion proteins (e.g., Fc fusion proteins, chimeric cytokines), other recombinant proteins (e.g., glycosylated proteins, enzymes, hormones), viral therapeutics (e.g., anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy), cell therapeutics (e.g., pluripotent stem cells, mesenchymal stem cells and adult stem cells), vaccines or lipid-encapsulated particles (e.g., exosomes, virus-like particles), RNA (such as e.g. siRNA) or DNA (such as e.g. plasmid DNA), antibiotics or amino acids. In embodiments, the devices, facilities and methods can be used for producing biosimilars.
As mentioned, in embodiments, devices, facilities and methods allow for the production of eukaryotic cells, e.g., mammalian cells or lower eukaryotic cells such as for example yeast cells or filamentous fungi cells, or prokaryotic cells such as Gram-positive or Gram-negative cells and/or products of the eukaryotic or prokaryotic cells, e.g., proteins, peptides, antibiotics, amino acids, nucleic acids (such as DNA or RNA), synthesised by the eukaryotic cells in a large-scale manner. Unless stated otherwise herein, the devices, facilities, and methods can include any desired volume or production capacity including but not limited to bench-scale, pilot-scale, and full production scale capacities.
Moreover and unless stated otherwise herein, the devices, facilities, and methods can include any suitable reactor(s) including but not limited to stirred tank, airlift, fiber, microfiber, hollow fiber, ceramic matrix, fluidized bed, fixed bed, and/or spouted bed bioreactors. As used herein, “reactor” can include a fermentor or fermentation unit, or any other reaction vessel and the term “reactor” is used interchangeably with “fermentor.” For example, in some aspects, an example bioreactor unit can perform one or more, or all, of the following: feeding of nutrients and/or carbon sources, injection of suitable gas (e.g., oxygen), inlet and outlet flow of fermentation or cell culture medium, separation of gas and liquid phases, maintenance of temperature, maintenance of oxygen and CO2 levels, maintenance of pH level, agitation (e.g., stirring), and/or cleaning/sterilizing. Example reactor units, such as a fermentation unit, may contain multiple reactors within the unit, for example the unit can have 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 45, 50, 60, 70, 80, 90, or 100, or more bioreactors in each unit and/or a facility may contain multiple units having a single or multiple reactors within the facility. In various embodiments, the bioreactor can be suitable for batch, semi fed-batch, fed-batch, perfusion, and/or a continuous fermentation processes. Any suitable reactor diameter can be used. In embodiments, the bioreactor can have a volume between about 100 mL and about 50,000 L. Non-limiting examples include a volume of 100 mL, 250 mL, 500 mL, 750 mL, 1 liter, 2 liters, 3 liters, 4 liters, 5 liters, 6 liters, 7 liters, 8 liters, 9 liters, 10 liters, 15 liters, 20 liters, 25 liters, 30 liters, liters, 50 liters, 60 liters, 70 liters, 80 liters, 90 liters, 100 liters, 150 liters, 200 liters, 250 liters, 300 liters, 350 liters, 400 liters, 450 liters, 500 liters, 550 liters, 600 liters, 650 liters, 700 liters, 750 liters, 800 liters, 850 liters, 900 liters, 950 liters, 1000 liters, 1500 liters, 2000 liters, 2500 liters, 3000 liters, 3500 liters, 4000 liters, 4500 liters, 5000 liters, 6000 liters, 7000 liters, 8000 liters, 9000 liters, 10,000 liters, 15,000 liters, 20,000 liters, and/or 50,000 liters. Additionally, suitable reactors can be multi-use, single-use, disposable, or non-disposable and can be formed of any suitable material including metal alloys such as stainless steel (e.g., 316L or any other suitable stainless steel) and Inconel, plastics, and/or glass.
In embodiments and unless stated otherwise herein, the devices, facilities, and methods described herein can also include any suitable unit operation and/or equipment not otherwise mentioned, such as operations and/or equipment for separation, purification, and isolation of such products. Any suitable facility and environment can be used, such as traditional stick-built facilities, modular, mobile and temporary facilities, or any other suitable construction, facility, and/or layout. For example, in some embodiments modular clean-rooms can be used. Additionally and unless otherwise stated, the devices, systems, and methods described herein can be housed and/or performed in a single location or facility or alternatively be housed and/or performed at separate or multiple locations and/or facilities.
By way of non-limiting examples and without limitation, U.S. Publication Nos. 2013/0280797; 2012/0077429; 2011/0280797; 2009/0305626; and U.S. Pat. Nos. 8,298,054; 7,629,167; and 5,656,491, which are hereby incorporated by reference in their entirety, describe example facilities, equipment, and/or systems that may be suitable.
In embodiments, the cells are eukaryotic cells, e.g., mammalian cells. The mammalian cells can be for example human or rodent or bovine cell lines or cell strains. Examples of such cells, cell lines or cell strains are e.g. mouse myeloma (NSO)-cell lines, Chinese hamster ovary (CHO)-cell lines, HT1080, H9, HepG2, MCF7, MDBK Jurkat, NIH3T3, PC12, BHK (baby hamster kidney cell), VERO, SP2/0, YB2/0, YO, C127, L cell, COS, e.g., COS1 and COS7, QC1-3, HEK-293, VERO, PER.C6, HeLA, EBI, EB2, EB3, oncolytic or hybridoma-cell lines. Preferably the mammalian cells are CHO-cell lines. In one embodiment, the cell is a CHO cell. In one embodiment, the cell is a CHO-K1 cell, a CHO-K1 SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHOS, a CHO GS knock-out cell, a CHO FUT8 GS knock-out cell, a CHOZN, or a CHO-derived cell. The CHO GS knock-out cell (e.g., GSKO cell) is, for example, a CHO-K1 SV GS knockout cell. The CHO FUT8 knockout cell is, for example, the Potelligent® CHOK1 SV (Lonza Biologics, Inc.). Eukaryotic cells can also be avian cells, cell lines or cell strains, such as for example, EBx® cells, EB14, EB24, EB26, EB66, or EBvl3.
In one embodiment, the eukaryotic cells are stem cells. The stem cells can be, for example, pluripotent stem cells, including embryonic stem cells (ESCs), adult stem cells, induced pluripotent stem cells (iPSCs), tissue specific stem cells (e.g., hematopoietic stem cells) and mesenchymal stem cells (MSCs).
In one embodiment, the cells are for cell therapy.
In one embodiment, the cells may include T cells, or immune cells. For instance, the cells can include B cells, natural killer cells, dendritic cells, tumor infiltrating lymphocytes, monocytes, megakaryocytes, or the like.
In one embodiment, the cell is a differentiated form of any of the cells described herein. In one embodiment, the cell is a cell derived from any primary cell in culture.
In embodiments, the cell is a hepatocyte such as a human hepatocyte, animal hepatocyte, or a non-parenchymal cell. For example, the cell can be a plateable metabolism qualified human hepatocyte, a plateable induction qualified human hepatocyte, plateable Qualyst Transporter Certified™ human hepatocyte, suspension qualified human hepatocyte (including 10-donor and 20-donor pooled hepatocytes), human hepatic kupffer cells, human hepatic stellate cells, dog hepatocytes (including single and pooled Beagle hepatocytes), mouse hepatocytes (including CD-1 and C57B1/6 hepatocytes), rat hepatocytes (including Sprague-Dawley, Wistar Han, and Wistar hepatocytes), monkey hepatocytes (including Cynomolgus or Rhesus monkey hepatocytes), cat hepatocytes (including Domestic Shorthair hepatocytes), and rabbit hepatocytes (including New Zealand White hepatocytes). Example hepatocytes are commercially available from Triangle Research Labs, LLC, 6 Davis Drive Research Triangle Park, North Carolina, USA 27709.
In one embodiment, the eukaryotic cell is a lower eukaryotic cell such as e.g. a yeast cell (e.g., Pichia genus (e.g. Pichia pastoris, Pichia methanolica, Pichia kluyveri, and Pichia angusta), Komagataella genus (e.g. Komagataella pastoris, Komagataella pseudopastoris or Komagataella phaffii), Saccharomyces genus (e.g. Saccharomyces cerevisae, cerevisiae, Saccharomyces kluyveri, Saccharomyces uvarum), Kluyveromyces genus (e.g. Kluyveromyces lactis, Kluyveromyces marxianus), the Candida genus (e.g. Candida utilis, Candida cacaoi, Candida boidinii), the Geotrichum genus (e.g. Geotrichum fermentans), Hansenula polymorpha, Yarrowia lipolytica, or Schizosaccharomyces pombe. Preferred is the species Pichia pastoris. Examples for Pichia pastoris strains are X33, GS115, KM71, KM71H; and CBS7435.
In one embodiment, the eukaryotic cell is a fungal cell (e.g. Aspergillus (such as A. niger, A. fumigatus, A. orzyae, A. nidula), Acremonium (such as A. thermophilum), Chaetomium (such as C. thermophilum), Chrysosporium (such as C. thermophile), Cordyceps (such as C. militaris), Corynascus, Ctenomyces, Fusarium (such as F. oxysporum), Glomerella (such as G. graminicola), Hypocrea (such as H. jecorina), Magnaporthe (such as M. orzyae), Myceliophthora (such as M. thermophile), Nectria (such as N. heamatococca), Neurospora (such as N. crassa), Penicillium, Sporotrichum (such as S. thermophile), Thielavia (such as T. terrestris, T. heterothallica), Trichoderma (such as T. reesei), or Verticillium (such as V. dahlia)).
In one embodiment, the eukaryotic cell is an insect cell (e.g., Sf9, Mimic™ Sf9, Sf21, High Five™ (BT1-TN-5B1-4), or BT1-Ea88 cells), an algae cell (e.g., of the genus Amphora, Bacillariophyceae, Dunaliella, Chlorella, Chlamydomonas, Cyanophyta (cyanobacteria), Nannochloropsis, Spirulina, or Ochromonas), or a plant cell (e.g., cells from monocotyledonous plants (e.g., maize, rice, wheat, or Setaria), or from a dicotyledonous plants (e.g., cassava, potato, soybean, tomato, tobacco, alfalfa, Physcomitrella patens or Arabidopsis).
In one embodiment, the cell is a bacterial or prokaryotic cell.
In embodiments, the prokaryotic cell is a Gram-positive cells such as Bacillus, Streptomyces Streptococcus, Staphylococcus or Lactobacillus. Bacillus that can be used is, e.g. the B. subtilis, B. amyloliquefaciens, B. licheniformis, B. natto, or B. megaterium. In embodiments, the cell is B. subtilis, such as B. subtilis 3NA and B. subtilis 168. Bacillus is obtainable from, e.g., the Bacillus Genetic Stock Center, Biological Sciences 556, 484 West 12th Avenue, Columbus OH 43210-1214.
In one embodiment, the prokaryotic cell is a Gram-negative cell, such as Salmonella spp. or Escherichia coli, such as e.g., TG1, TG2, W3110, DH1, DHB4, DH5a, HMS 174, HMS174 (DE3), NM533, C600, HB101, JM109, MC4100, XL1-Blue and Origami, as well as those derived from E. coli B-strains, such as for example BL-21 or BL21 (DE3), all of which are commercially available.
Suitable host cells are commercially available, for example, from culture collections such as the DSMZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany) or the American Type Culture Collection (ATCC).
In embodiments, the cultured cells are used to produce proteins e.g., antibodies, e.g., monoclonal antibodies, and/or recombinant proteins, for therapeutic use. In embodiments, the cultured cells produce peptides, amino acids, fatty acids or other useful biochemical intermediates or metabolites. For example, in embodiments, molecules having a molecular weight of about 4000 daltons to greater than about 140,000 daltons can be produced. In embodiments, these molecules can have a range of complexity and can include posttranslational modifications including glycosylation.
In embodiments, the protein is, e.g., BOTOX, Myobloc, Neurobloc, Dysport (or other serotypes of botulinum neurotoxins), alglucosidase alpha, daptomycin, YH-16, choriogonadotropin alpha, filgrastim, cetrorelix, interleukin-2, aldesleukin, teceleulin, denileukin diftitox, interferon alpha-n3 (injection), interferon alpha-nl, DL-8234, interferon, Suntory (gamma-1a), interferon gamma, thymosin alpha 1, tasonermin, DigiFab, ViperaTAb, EchiTAb, CroFab, nesiritide, abatacept, alefacept, Rebif, eptoterminalfa, teriparatide (osteoporosis), calcitonin injectable (bone disease), calcitonin (nasal, osteoporosis), etanercept, hemoglobin glutamer 250 (bovine), drotrecogin alpha, collagenase, carperitide, recombinant human epidermal growth factor (topical gel, wound healing), DWP401, darbepoetin alpha, epoetin omega, epoetin beta, epoetin alpha, desirudin, lepirudin, bivalirudin, nonacog alpha, Mononine, eptacog alpha (activated), recombinant Factor VIII+VWF, Recombinate, recombinant Factor VIII, Factor VIII (recombinant), Alphnmate, octocog alpha, Factor VIII, palifermin, Indikinase, tenecteplase, alteplase, pamiteplase, reteplase, nateplase, monteplase, follitropin alpha, rFSH, hpFSH, micafungin, pegfilgrastim, lenograstim, nartograstim, sermorelin, glucagon, exenatide, pramlintide, iniglucerase, galsulfase, Leucotropin, molgramostirn, triptorelin acetate, histrelin (subcutaneous implant, Hydron), deslorelin, histrelin, nafarelin, leuprolide sustained release depot (ATRIGEL), leuprolide implant (DUROS), goserelin, Eutropin, KP-102 program, somatropin, mecasermin (growth failure), enlfavirtide, Org-33408, insulin glargine, insulin glulisine, insulin (inhaled), insulin lispro, insulin deternir, insulin (buccal, RapidMist), mecasermin rinfabate, anakinra, celmoleukin, 99 mTc-apcitide injection, myelopid, Betaseron, glatiramer acetate, Gepon, sargramostim, oprelvekin, human leukocyte-derived alpha interferons, Bilive, insulin (recombinant), recombinant human insulin, insulin aspart, mecasenin, Roferon-A, interferon-alpha 2, Alfaferone, interferon alfacon-1, interferon alpha, Avonex′ recombinant human luteinizing hormone, dornase alpha, traferm in, ziconotide, taltirelin, diboterminalfa, atosiban, becaplerm in, eptifibatide, Zemaira, CTC-111, Shanvac-B, HPV vaccine (quadrivalent), octreotide, lanreotide, ancestirn, agalsidase beta, agalsidase alpha, laronidase, prezatide copper acetate (topical gel), rasburicase, ranibizumab, Actimmune, PEG-Intron, Tricomin, recombinant house dust mite allergy desensitization injection, recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis), epoetin delta, transgenic antithrombin III, Granditropin, Vitrase, recombinant insulin, interferon-alpha (oral lozenge), GEM-21S, vapreotide, idursulfase, omnapatrilat, recombinant serum albumin, certolizumab pegol, glucarpidase, human recombinant Cl esterase inhibitor (angioedema), lanoteplase, recombinant human growth hormone, enfuvirtide (needle-free injection, Biojector 2000), VGV-1, interferon (alpha), lucinactant, aviptadil (inhaled, pulmonary disease), icatibant, ecallantide, omiganan, Aurograb, pexigananacetate, ADI-PEG-20, LDI-200, degarelix, cintredelinbesudotox, Favld, MDX-1379, ISAtx-247, liraglutide, teriparatide (osteoporosis), tifacogin, AA4500, T4N5 liposome lotion, catumaxomab, DWP413, ART-123, Chrysalin, desmoteplase, amediplase, corifollitropinalpha, TH-9507, teduglutide, Diamyd, DWP-412, growth hormone (sustained release injection), recombinant G-CSF, insulin (inhaled, AIR), insulin (inhaled, Technosphere), insulin (inhaled, AERx), RGN-303, DiaPep277, interferon beta (hepatitis C viral infection (HCV)), interferon alpha-n3 (oral), belatacept, transdermal insulin patches, AMG-531, MBP-8298, Xerecept, opebacan, AIDSVAX, GV-1001, LymphoScan, ranpirnase, Lipoxysan, lusupultide, MP52 (beta-tricalciumphosphate carrier, bone regeneration), melanoma vaccine, sipuleucel-T, CTP-37, Insegia, vitespen, human thrombin (frozen, surgical bleeding), thrombin, TransMlD, alfimeprase, Puricase, terlipressin (intravenous, hepatorenal syndrome), EUR-1008M, recombinant FGF-I (injectable, vascular disease), BDM-E, rotigaptide, ETC-216, P-113, MBI-594AN, duramycin (inhaled, cystic fibrosis), SCV-07, OPI-45, Endostatin, Angiostatin, ABT-510, Bowman Birk Inhibitor Concentrate, XMP-629, 99 mTc-Hynic-Annexin V, kahalalide F, CTCE-9908, teverelix (extended release), ozarelix, rornidepsin, BAY-504798, interleukin4, PRX-321, Pepscan, iboctadekin, rhlactoferrin, TRU-015, IL-21, ATN-161, cilengitide, Albuferon, Biphasix, IRX-2, omega interferon, PCK-3145, CAP-232, pasireotide, huN901-DMI, ovarian cancer immunotherapeutic vaccine, SB-249553, Oncovax-CL, OncoVax-P, BLP-25, CerVax-16, multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), nemifitide, rAAT (inhaled), rAAT (dermatological), CGRP (inhaled, asthma), pegsunercept, thymosinbeta4, plitidepsin, GTP-200, ramoplanin, GRASPA, OBI-1, AC-100, salmon calcitonin (oral, eligen), calcitonin (oral, osteoporosis), examorelin, capromorelin, Cardeva, velafermin, 131I-TM-601, KK-220, T-10, ularitide, depelestat, hematide, Chrysalin (topical), rNAPc2, recombinant Factor V111 (PEGylated liposomal), bFGF, PEGylated recombinant staphylokinase variant, V-10153, SonoLysis Prolyse, NeuroVax, CZEN-002, islet cell neogenesis therapy, rGLP-1, BIM-51077, LY-548806, exenatide (controlled release, Medisorb), AVE-0010, GA-GCB, avorelin, ACM-9604, linaclotid eacetate, CETi-1, Hemospan, VAL (injectable), fast-acting insulin (injectable, Viadel), intranasal insulin, insulin (inhaled), insulin (oral, eligen), recombinant methionyl human leptin, pitrakinra subcutancous injection, eczema), pitrakinra (inhaled dry powder, asthma), Multikine, RG-1068, MM-093, NBI-6024, AT-001, PI-0824, Org-39141, Cpn10 (autoimmune diseases/inflammation), talactoferrin (topical), rEV-131 (ophthalmic), rEV-131 (respiratory disease), oral recombinant human insulin (diabetes), RPI-78M, oprelvekin (oral), CYT-99007 CTLA4-Ig, DTY-001, valategrast, interferon alpha-n3 (topical), IRX-3, RDP-58, Tauferon, bile salt stimulated lipase, Merispase, alaline phosphatase, EP-2104R, Melanotan-II, bremelanotide, ATL-104, recombinant human microplasmin, AX-200, SEMAX, ACV-1, Xen-2174, CJC-1008, dynorphin A, SI-6603, LAB GHRH, AER-002, BGC-728, malaria vaccine (virosomes, PeviPRO), ALTU-135, parvovirus B19 vaccine, influenza vaccine (recombinant neuraminidase), malaria/HBV vaccine, anthrax vaccine, Vacc-5q, Vacc-4x, HIV vaccine (oral), HPV vaccine, Tat Toxoid, YSPSL, CHS-13340, PTH(1-34) liposomal cream (Novasome), Ostabolin-C, PTH analog (topical, psoriasis), MBRI-93.02, MTB72F vaccine (tuberculosis), MVA-Ag85A vaccine (tuberculosis), FARA04, BA-210, recombinant plague FIV vaccine, AG-702, OxSODrol, rBetV1, Der-p1/Der-p2/Der-p7 allergen-targeting vaccine (dust mite allergy), PR1 peptide antigen (leukemia), mutant ras vaccine, HPV-16 E7 lipopeptide vaccine, labyrinthin vaccine (adenocarcinoma), CML vaccine, WT1-peptide vaccine (cancer), IDD-5, CDX-110, Pentrys, Norelin, CytoFab, P-9808, VT-111, icrocaptide, telbermin (dermatological, diabetic foot ulcer), rupintrivir, reticulose, rGRF, HA, alpha-galactosidase A, ACE-011, ALTU-140, CGX-1160, angiotensin therapeutic vaccine, D-4F, ETC-642, APP-018, rhMBL, SCV-07 (oral, tuberculosis), DRF-7295, ABT-828, ErbB2-specific immunotoxin (anticancer), DT3SSIL-3, TST-10088, PRO-1762, Combotox, cholecystokinin-B/gastrin-receptor binding peptides, 111In-hEGF, AE-37, trasnizumab-DM1, Antagonist G, IL-12 (recombinant), PM-02734, IMP-321, rhIGF-BP3, BLX-883, CUV-1647 (topical), L-19 based radioimmunotherapeutics (cancer), Re-188-P-2045, AMG-386, DC/1540/KLH vaccine (cancer), VX-001, AVE-9633, AC-9301, NY-ESO-1 vaccine (peptides), NA17.A2 peptides, melanoma vaccine (pulsed antigen therapeutic), prostate cancer vaccine, CBP-501, recombinant human lactoferrin (dry eye), FX-06, AP-214, WAP-8294A (injectable), ACP-HIP, SUN-11031, peptide YY [3-36] (obesity, intranasal), FGLL, atacicept, BR3-Fc, BN-003, BA-058, human parathyroid hormone 1-34 (nasal, osteoporosis), F-18-CCR1, AT-1100 (celiac disease/diabetes), JPD-003, PTH(7-34) liposomal cream (Novasome), duramycin (ophthalmic, dry eye), CAB-2, CTCE-0214, GlycoPEGylated erythropoietin, EPO-Fc, CNTO-528, AMG-114, JR-013, Factor XIII, aminocandin, PN-951, 716155, SUN-E7001, TH-0318, BAY-73-7977, teverelix (immediate release), EP-51216, hGH (controlled release, Biosphere), OGP-I, sifuvirtide, TV4710, ALG-889, Org-41259, rhCC10, F-991, thymopentin (pulmonary diseases), r(m)CRP, hepatoselective insulin, subalin, L19-IL-2 fusion protein, elafin, NMK-150, ALTU-139, EN-122004, rhTPO, thrombopoietin receptor agonist (thrombocytopenic disorders), AL-108, AL-208, nerve growth factor antagonists (pain), SLV-317, CGX-1007, INNO-105, oral teriparatide (eligen), GEM-OSi, AC-162352, PRX-302, LFn-p24 fusion vaccine (Therapore), EP-1043, S pneumoniae pediatric vaccine, malaria vaccine, Neisseria meningitidis Group B vaccine, neonatal group B streptococcal vaccine, anthrax vaccine, HCV vaccine (gpE1+gpE2+MF-59), otitis media therapy, HCV vaccine (core antigen+ISCOMATRIX), hPTH(1-34) (transdermal, ViaDerm), 768974, SYN-101, PGN-0052, aviscumnine, BIM-23190, tuberculosis vaccine, multi-epitope tyrosinase peptide, cancer vaccine, enkastim, APC-8024, GI-5005, ACC-001, TTS-CD3, vascular-targeted TNF (solid tumors), desmopressin (buccal controlled-release), onercept, and TP-9201.
In some embodiments, the polypeptide is adalimumab (HUMIRA), infliximab (REMICADE™), rituximab (RITUXAN™/MAB THERA™) etanercept (ENBREL™), bevacizumab (AVASTIN™), trastuzumab (HERCEPTIN™), pegrilgrastim (NEULASTA™), or any other suitable polypeptide including biosimilars and biobetters.
Other suitable polypeptides are those listed below and in Table 1 of US2016/0097074:
In embodiments, the polypeptide is a hormone, blood clotting/coagulation factor, cytokine/growth factor, antibody molelcule, fusion protein, protein vaccine, or peptide as shown in Table 2.
In embodiments, the protein is multispecific protein, e.g., a bispecific antibody as shown in Table 3.
These and other modifications and variations to the present invention may be practiced by those of ordinary skill in the art, without departing from the spirit and scope of the present invention, which is more particularly set forth in the appended claims. In addition, it should be understood that aspects of the various embodiments may be interchanged both in whole or in part. Furthermore, those of ordinary skill in the art will appreciate that the foregoing description is by way of example only and is not intended to limit the invention so further described in such appended claims.
This application claims priority to and the benefit of U.S. Provisional Application No. 63/127,337, filed Dec. 18, 2020 and PCT Application No. PCT/US2021/063840, filed Dec. 16, 2021, the contents of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2021/063840 | 12/16/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63127337 | Dec 2020 | US |
